Results 161 to 170 of about 27,469 (292)

Clinical Significance of Biomarkers in Oropharyngeal Squamous Cell Carcinoma: Recurrence Prediction and Treatment Response

Cancer Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background Oropharyngeal squamous cell carcinoma (OPSCC) accounts for a substantial proportion of head and neck cancers, with a rising incidence largely driven by human papillomavirus (HPV) infection. Despite advances in multimodal treatment, disease recurrence remains common and limits long‐term survival, highlighting the need for reliable ...
Yunxia Chen, Wenyu Zhang, Xiang Gao, Kongling Xing, Yijing Ren, Jinyu Hu, Zhihao Xie, Ping Zhou   +7 more
wiley   +1 more source

Intratumoral Microorganisms in Tumors: Current Understanding and Emerging Therapeutic Strategies

MedComm, Volume 7, Issue 5, May 2026.
Tumors are no longer viewed as sterile but dynamic ecosystems harboring low‐biomass intratumoral microbiota. These microbes, derived from gut, oral cavity, or circulation, shape tumorigenesis and therapy response via core mechanisms: immunomodulation (regulating T cells, macrophages), metabolic reprogramming (SCFAs, indoles, bile acids), chronic ...
Haoling Zhang, Zengkan Du, Ping Lu, Aimin Jiang, Yadong Guo, Yawei Liu, Zhijing Song, Bing Dai, Wangzheqi Zhang   +8 more
wiley   +1 more source

Radioiodination of Two Carborane‐Based Dual Cyclooxygenase‐2/5‐Lipoxygenase Inhibitors and Their In Vitro and In Vivo Evaluation

ChemBioChem, Volume 27, Issue 7, 14 April 2026.
Two dicarbadodecaborane(12)‐based dual cyclooxygenase‐2/5‐lipoxygenase (COX‐2/5‐LO) inhibitors were 123I‐labeled. Refinement of labeling and formulation conditions and extensive in vitro characterization are presented. Cell uptake studies in COX‐2‐ and 5‐LO‐overexpressing cell lines showed COX‐2‐independent and partly 5‐LO‐dependent uptake.
Jonas Schädlich, Martin Ullrich, Cathleen Haase‐Kohn, Robert Wodtke, Sebastian Braun, Maximilian Molitor, Bettina Hofmann, Dieter Steinhilber, Klaus Kopka, Evamarie Hey‐Hawkins, Jens Pietzsch, Markus Laube   +11 more
wiley   +1 more source

pH- and Ultrasound-Responsive Paclitaxel-Loaded Carboxymethyl Chitosan Nanodroplets for Combined Imaging and Synergistic Chemoradiotherapy

International Journal of Nanomedicine, 2020
Mengmeng Shang,1 Xiao Sun,1 Lu Guo,1 Dandan Shi,1 Ping Liang,2 Dong Meng,1 Xiaoying Zhou,1 Xinxin Liu,1 Yading Zhao,1 Jie Li1 1Department of Ultrasound, Qilu Hospital of Shandong University, Jinan 250012, People’s Republic of China; 2Department of ...
Shang M, Sun X, Guo L, Shi D, Liang P, Meng D, Zhou X, Liu X, Zhao Y, Li J   +9 more
doaj  

Radiosensitive Adamantinoma [PDF]

BMJ, 1963
openaire   +2 more sources

Cisplatin during radiation for head and neck cancer: insights from NRG Oncology experience. [PDF]

J Natl Cancer Inst
Sousa LG, Edward Bates J, Anand P, Caudell JJ, Colevas AD, Runge CL, Sharon JD, Awan M, Beadle BM, Choe JH, Gidley PW, Harari PM, Henson C, Katzel JA, Lee NY, McDowell L, Mell LK, Nader ME, Rudra S, Wang K, Yang G, Yom SS, Wise-Draper TM.   +22 more
europepmc   +1 more source

Melittin Acts as a Radiosensitizer for Non-Small Cell Lung Cancer by Inhibiting the DNA Damage Repair System and Inducing Apoptosis. [PDF]

Yonsei Med J
Seo E, Seo H, Kim KO, Lee KC.
europepmc   +1 more source

Maximum Likelihood Estimation of the Prevalence of nonlethal Neoplasms [PDF]

, 1982
Chameaud, J., Chmelevsky, D., Kellerer, Albrecht M., Lafuma, J.   +3 more
core   +1 more source

Compound Library Screening Identified Cladribine as a Novel Radiosensitizer for Prostate Cancer. [PDF]

Cancer Sci
Oka T, Hatano K, Katsuki S, Kanaki T, Inoguchi S, Tani M, Yoshimura A, Horibe Y, Liu Y, Sassi N, Okuda Y, Yamamoto A, Uemura T, Yamamichi G, Ishizuya Y, Hayashi T, Yamamoto Y, Kato T, Kawashima A, Tamari K, Lin B, Tani A, Tsujikawa K, Takahashi Y, Ogawa K, Lupold SE, Nonomura N.   +26 more
europepmc   +1 more source

Hybrid biomaterials-based radiosensitizers: Preparations and their applications in enhancing tumor radiotherapy. [PDF]

Mater Today Bio
Liu J, Zhao L, Sun Y, Fu Q, Xiao W.
europepmc   +1 more source